Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma

Emanuela Minna; Paola Romeo; Matteo Dugo; Loris De Cecco; Katia Todoerti; Silvana Pilotti; Federica Perrone; Ettore Seregni; Luca Agnelli; Antonino Neri; Angela Greco; Maria Grazia Borrello

doi:10.18632/oncotarget.24557

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma

PDF | How to cite

Oncotarget. 2018; 9:12534-12534. https://doi.org/10.18632/oncotarget.24557

Metrics: PDF 1778 views | ?

Emanuela Minna¹, Paola Romeo¹, Matteo Dugo², Loris De Cecco², Katia Todoerti³, Silvana Pilotti⁴, Federica Perrone⁴, Ettore Seregni⁵, Luca Agnelli⁶, Antonino Neri^6,7, Angela Greco¹ and Maria Grazia Borrello¹

¹ Department of Experimental Oncology and Molecular Medicine, Molecular Mechanisms Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
² Department of Experimental Oncology and Molecular Medicine, Functional Genomics Core Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
³ Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture (PZ), Italy
⁴ Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
⁵ Department of Diagnostic Imaging and Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
⁶ Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
⁷ Hematology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

Published: February 23, 2018

This article has been corrected: The updated Grant information is provided below

GRANT SUPPORT

This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, Grant IG10366 to M.G. Borrello and Grant IG13307 to E. Seregni), by Ministero della Salute (Ricerca Finalizzata 2013 RF-2013-02354985) and in part by funds obtained through an Italian law that allows taxpayers to allocate 0.5 percent share of their income tax contribution to a research institution of their choice.

Original article: Oncotarget. 2016; 7:12731-12747. DOI: https://doi.org/10.18632/oncotarget.7262.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24557

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma